Semax vs Selank Research Compared: Mechanisms, Neuroregulation, and Cognitive Targets

Semax operates primarily through upregulation of BDNF (brain-derived neurotrophic factor) and modulation of dopaminergic and serotonergic transmission. It was originally developed for stroke and optic nerve injury and is registered in Russia for these applications. Its effects in research models are characterized as stimulatory, procognitive, and neuroprotective.

Selank operates primarily through GABA-A receptor modulation and regulation of enkephalin-degrading enzymes (specifically aminopeptidase P). It was developed as an anxiolytic and is registered in Russia for anxiety disorders. Its effects are characterized as anxiolytic (reducing anxiety without sedation), stress-regulatory, and mildly procognitive through the anxiety-reduction pathway.

The two compounds share BDNF elevation as a common downstream effect, but through different upstream mechanisms and with different primary research applications. For individual compound deep dives, see the Semax guide, Semax clinical evidence review, Selank guide, and Selank vs Semax comparison.

ACTH fragment (adrenocorticotropic hormone fragment): The 4-10 amino acid segment of the ACTH peptide hormone. This fragment lacks the steroidogenic effects of full ACTH but retains neurotrophic activity. Semax is a synthetic analog of this fragment with added Pro-Gly-Pro extension for stability.

Tuftsin: A natural tetrapeptide (Thr-Lys-Pro-Arg) produced by cleavage of IgG. Active in immune modulation and CNS function. Selank is a synthetic analog of tuftsin with an added tripeptide extension (Gly-Glu-Thr) for stability.

GABA-A modulation: Modulation of the GABA-A receptor, the principal inhibitory receptor in the CNS. GABA-A modulators can produce anxiolytic, sedative, or anticonvulsant effects depending on the specific binding site and degree of modulation. Selank modulates (rather than directly agonizes) GABA-A, producing anxiolysis without sedation.

BDNF (brain-derived neurotrophic factor): The primary neurotrophin for neuronal survival, synaptic plasticity, and cognitive function. Elevated BDNF is associated with improved learning, memory, and resilience to neurological stress.

Anxiolytic: A compound that reduces anxiety. Distinguished from sedatives by the ability to reduce anxiety without significant drowsiness or motor impairment at research doses.

Neuroprotection: Protection of neurons from damage, death, or functional decline due to injury, ischemia, or neurotoxic insult.

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is an analog of the ACTH 4-10 fragment with a Pro-Gly-Pro C-terminal extension that increases stability against peptidase degradation.

Its primary mechanism involves upregulation of BDNF and NGF in the hippocampus and frontal cortex, demonstrating 2-3 fold BDNF elevation in published animal studies. Semax also modulates dopaminergic and serotonergic systems, increasing dopamine synthesis and utilization in striatal regions and elevating serotonin turnover in hippocampal circuits. This combined BDNF-plus-monoamine mechanism produces a stimulatory, procognitive effect profile.

Clinically, Semax is registered in Russia for: ischemic stroke (as an adjunct to thrombolysis), optic nerve atrophy, and neurasthenia. The intranasal formulation (1% solution) is the registered clinical form. Published Russian clinical data supports cognitive improvement in stroke rehabilitation and neuroprotection in optic nerve damage models.

For full Semax research context, see the Semax guide and Semax clinical evidence review.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed at the same Russian Academy of Sciences institute as Semax. It is an analog of tuftsin (Thr-Lys-Pro-Arg) with the same Pro-Gly-Pro stabilizing C-terminal extension.

Its primary mechanism involves GABA-A receptor modulation through allosteric potentiation of the GABA-A receptor complex. This is distinct from benzodiazepine-class GABA-A agonism: Selank modulates the receptor at a different binding site, producing anxiolytic effects without the sedation, cognitive impairment, or dependence potential associated with direct GABA-A agonists. Selank also inhibits enkephalin-degrading enzymes (aminopeptidase P and dipeptidyl peptidase IV), increasing enkephalin availability in CNS circuits involved in stress and anxiety regulation.

Selank elevates BDNF as a secondary effect, potentially through reduced glucocorticoid stress-axis suppression (stress hormones chronically suppress BDNF; Selank's anxiolytic mechanism reduces this suppression). This BDNF elevation pathway is indirect and distinct from Semax's direct ACTH receptor-mediated BDNF upregulation.

Selank is registered in Russia for generalized anxiety disorder treatment. Published clinical data demonstrates anxiolytic efficacy comparable to standard-of-care benzodiazepines with a more favorable side-effect profile in registered trial data. For full context, see the Selank guide and Selank vs Semax comparison.

A structured comparison of the two compounds clarifies where they diverge and where they converge.

The critical insight from this comparison is that these compounds occupy distinct positions in the cognitive neuroscience landscape. Semax is the more appropriate study tool for researchers interested in cognition enhancement, BDNF upregulation, and neuroprotection. Selank is more relevant for researchers studying anxiolytic mechanisms, stress regulation, and GABA-A modulation without sedation.

Semax has been studied most extensively in stroke rehabilitation and cognitive impairment recovery models. Published Russian clinical data describes improved cognitive performance on standardized neuropsychological batteries in stroke patients receiving intranasal Semax as an adjunct to standard therapy. Animal model data shows improved learning and memory in rodent cognitive impairment assays, attributed to BDNF and monoamine modulation.

Selank's cognitive research shows a different profile. Rather than directly enhancing cognitive performance in healthy subjects, Selank's published benefits tend to emerge through anxiety reduction: by decreasing chronic stress and anxiety, it removes the cognitive impairment that anxiety produces. Published research using Selank in anxious populations shows improved attention, processing speed, and working memory, but these gains appear to be mediated through reduced anxiety burden rather than direct nootropic action.

For researchers interested in the cognitive neuroscience of anxiety and stress, this distinction matters: Semax is more appropriate for studying direct cognitive enhancement; Selank is more appropriate for studying cognitive rescue from anxiety or stress-induced impairment. Both approaches are scientifically valid and address different research questions.

For broader cognitive peptide context, see the peptides for brain health guide and cognitive peptides compared.

In published anxiety and stress research, Selank's GABA-A modulation mechanism gives it a clear differentiation from Semax. Registered Russian trials compared Selank to standard benzodiazepine treatment in generalized anxiety disorder and found comparable anxiolytic efficacy with significantly lower side-effect burden, particularly in sedation, cognitive blunting, and dependence indicators.

Published animal model stress research shows Selank reducing corticosterone responses to acute stress (a measure of hypothalamic-pituitary-adrenal axis activation), protecting against chronic unpredictable stress-induced behavioral changes, and maintaining normal learning performance under stress conditions where control animals showed stress-induced impairment.

Semax shows some anxiolytic and anti-stress activity in published models, attributed in part to its serotonergic effects and BDNF elevation. However, the magnitude of anxiolytic effect in published research is smaller for Semax than for Selank, and Semax's mechanism is not primarily designed for this application.

Semax's neuroprotective research profile is deeper than Selank's. The Russian clinical registration for ischemic stroke and optic nerve atrophy reflects a body of published evidence showing Semax reduces neuronal apoptosis in ischemic conditions, accelerates neurological recovery after stroke, and protects optic nerve tissue from atrophic damage.

The neuroprotection mechanism involves BDNF's anti-apoptotic effects on neurons under stress, combined with VEGF upregulation (published data shows Semax elevates VEGF in ischemic brain regions) and reduced inflammatory cytokine production in acute CNS injury. These mechanisms are particularly relevant to TBI and stroke research contexts.

For Semax's neuroprotection research in TBI context, see the peptides for TBI research article. For the broader neuroprotection landscape, see neuroprotection peptide research.

For researchers designing cognitive neuroscience studies, the choice between Semax and Selank depends on the research question.

Semax is the more appropriate compound for: BDNF elevation studies, direct cognitive enhancement research, neuroprotection models, stroke and ischemia research, and monoamine modulation studies. Its stimulatory profile and direct BDNF mechanism make it the lead compound for these applications.

Selank is more appropriate for: anxiolytic mechanism studies, GABA-A modulation without sedation research, stress regulation models, enkephalin system research, and studies of anxiety-induced cognitive impairment. Its calming profile and indirect cognitive effects make it distinct from Semax in research design terms.

For researchers interested in studying both simultaneously, their mechanistic non-redundancy means they could be studied in parallel or in combination without major pathway overlap. For detailed context on multi-compound cognitive research design, see the nootropic peptide stack guide and peptide administration routes.

The full Blackwell cognitive research library provides comprehensive resources for researchers in this area. Individual compound guides: Semax, Selank, Cerebrolysin, Dihexa, NAD+.

Deep-dive evidence reviews: Semax clinical evidence review, Cerebrolysin Alzheimer's evidence, Dihexa HGF/c-Met research.

Comparison and context: Cognitive peptides compared, Peptides for brain health, BDNF neuroplasticity explained, Neuroprotection peptide research.